Genopole® is France’s leading biotech- and biotherapy-dedicated science and business park
The Genopole® project was initiated in 1998 in the town of Evry-Corbeil (in the Essonne county, just south of Paris), under the impetus of the French government, Ile-de-France Regional Council, Essonne County Council and the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM); the goal was to create France’s first ever science and business park dedicated to genomics, genetics and biotech and help the country to catch up with its international rivals in these fields.
By modeling itself on world-class North American and European bioclusters, Genopole® has pioneered this approach in France.
In addition to constant support from its founding members and other partners, Genopole®’s success is largely based on the novelty of its approach: bringing together public- and private-sector research labs, university teaching facilities and life science start-ups on a single campus in Evry–Corbeil.
- 73 biotech companies
- 21 academic research labs
- 18 shared-access technology platforms and technical facilities
- 91,929 m2 of real estate
- €292,73 million in equity funding raised by Genopole® companies
- 31 products in development or on the market, from the regulatory preclinical phase through to market launch
- 2 107 direct jobs